Cargando…
Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era
PURPOSE OF REVIEW: Despite significant advances in detection and treatment for breast cancer, the breast cancer mortality rate for Black women remains 40% higher than that for White women. Timely work-up and treatment improve outcomes, yet no gold standard exists for which to guide providers. RECENT...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735127/ https://www.ncbi.nlm.nih.gov/pubmed/36530340 http://dx.doi.org/10.1007/s12609-022-00469-9 |
_version_ | 1784846695687782400 |
---|---|
author | Fasano, Genevieve A. Bayard, Solange Gillot, Tamika Hannibal, Zuri Pedreira, Marian Newman, Lisa |
author_facet | Fasano, Genevieve A. Bayard, Solange Gillot, Tamika Hannibal, Zuri Pedreira, Marian Newman, Lisa |
author_sort | Fasano, Genevieve A. |
collection | PubMed |
description | PURPOSE OF REVIEW: Despite significant advances in detection and treatment for breast cancer, the breast cancer mortality rate for Black women remains 40% higher than that for White women. Timely work-up and treatment improve outcomes, yet no gold standard exists for which to guide providers. RECENT FINDINGS: A large body of literature demonstrates disparities in time to treatment for breast cancer, and most studies show that Black women receive treatment later than their White counterparts. The COVID-19 pandemic has been projected to worsen these disparities, but the extent of this impact remains unknown. SUMMARY: In this review, we describe the available evidence on disparities in time to treatment, potential drivers, and possible mitigation strategies. Future research must address how the COVID-19 pandemic has impacted the timely treatment of breast cancer patients, particularly populations vulnerable to disparate outcomes. Improved access to multidisciplinary breast programs, patient navigation services, and establishment of standards for timely treatment are necessary. |
format | Online Article Text |
id | pubmed-9735127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-97351272022-12-12 Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era Fasano, Genevieve A. Bayard, Solange Gillot, Tamika Hannibal, Zuri Pedreira, Marian Newman, Lisa Curr Breast Cancer Rep Breast Cancer Disparities (LA Newman, Section Editor) PURPOSE OF REVIEW: Despite significant advances in detection and treatment for breast cancer, the breast cancer mortality rate for Black women remains 40% higher than that for White women. Timely work-up and treatment improve outcomes, yet no gold standard exists for which to guide providers. RECENT FINDINGS: A large body of literature demonstrates disparities in time to treatment for breast cancer, and most studies show that Black women receive treatment later than their White counterparts. The COVID-19 pandemic has been projected to worsen these disparities, but the extent of this impact remains unknown. SUMMARY: In this review, we describe the available evidence on disparities in time to treatment, potential drivers, and possible mitigation strategies. Future research must address how the COVID-19 pandemic has impacted the timely treatment of breast cancer patients, particularly populations vulnerable to disparate outcomes. Improved access to multidisciplinary breast programs, patient navigation services, and establishment of standards for timely treatment are necessary. Springer US 2022-12-06 2022 /pmc/articles/PMC9735127/ /pubmed/36530340 http://dx.doi.org/10.1007/s12609-022-00469-9 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Breast Cancer Disparities (LA Newman, Section Editor) Fasano, Genevieve A. Bayard, Solange Gillot, Tamika Hannibal, Zuri Pedreira, Marian Newman, Lisa Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era |
title | Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era |
title_full | Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era |
title_fullStr | Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era |
title_full_unstemmed | Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era |
title_short | Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era |
title_sort | disparities in time to treatment for breast cancer: existing knowledge and future directions in the covid-19 era |
topic | Breast Cancer Disparities (LA Newman, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735127/ https://www.ncbi.nlm.nih.gov/pubmed/36530340 http://dx.doi.org/10.1007/s12609-022-00469-9 |
work_keys_str_mv | AT fasanogenevievea disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era AT bayardsolange disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era AT gillottamika disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era AT hannibalzuri disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era AT pedreiramarian disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era AT newmanlisa disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era |